Announced
Completed
Financials
Sources
Tags
Acquisition
Venture Capital
Completed
China
Private Equity
Cross Border
Biotechnology
Private
biotechnology products
Minority
Friendly
Synopsis
Private equity firm Qiming Venture Partners led a $106m Series D funding round in Asieris Pharmaceuticals, a developer of biotechnology products. Additional investors include YF Capital, CICC Capital, C&D, Gopher Asset Management, Hengxu Capital, IN Capital, V-Capital, Homsun Capital, IFSC, Triwise Capital, and Haoshuo Zhier Fund. “Apart from advancing competitive capacity, we are ready for drug commercialisation and manufacturing base construction. We also plan for new drugs listing toward soon-to-be done clinical trials or applications,” Kevin Pan, Asieris Founder and Chairman.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.